About this document
Immunotherapy Insights for Prostate Cancer by vincentzhou4617 is a document available to read on EtoBox.
The document presents clinical and translational results from the PORTER trial, a Phase 1 study evaluating combination immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). The trial assessed various nivolumab-based combinations, highlighting that pre-existing immune activation is crucial for clinical benefit, particularly in Cohort B, which combined radiation therapy with immune agents. Findings suggest that personalized immunotherapy regimens could improve treatment outcomes by tailor
- Author
- vincentzhou4617
- Language
- EN